Supramolecular ARB-NEP Complex for HFrEF Ejection Fraction Gain
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for heart failure with reduced ejection fraction (HFrEF) are inadequate, as evidenced by high mortality and rehospitalization rates, and existing drug combinations like LCZ696 and physical mixtures of angiotensin II receptor antagonists and NEP inhibitors do not provide sufficient therapeutic benefits.
Innovation Solution
A supramolecular complex of angiotensin II receptor antagonist metabolite (EXP3174) and NEP inhibitor (AHU377) is formulated into a medicament, with specific structural units and dosages tailored for oral administration, demonstrating improved efficacy over physical mixtures and existing drugs like LCZ696.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing drug combinations like LCZ696 and physical mixtures of angiotensin II receptor antagonists and NEP inhibitors are used, then treatment coverage is provided, but therapeutic benefits are insufficient
Solution Approach 1:
The patent combines angiotensin II receptor antagonist metabolite (EXP3174) and NEP inhibitor (AHU377) into a single supramolecular complex with specific stoichiometry (a:b where a and b are integers). This merging approach integrates two separate drugs into one formulation, providing dual therapeutic mechanisms while simplifying administration compared to physical mixtures, and achieving superior therapeutic benefits in HFrEF treatment.
2Reliability
If high doses of existing medications are administered to improve therapeutic effect, then mortality and rehospitalization rates may be reduced, but side effects and treatment complexity increase
Solution Approach 1:
By combining EXP3174 and AHU377 into a single supramolecular complex, the patent enables simultaneous delivery of two active ingredients at optimized ratios, potentially achieving better therapeutic outcomes at lower individual doses compared to separate administrations, thereby reducing side effects while maintaining treatment simplicity.
3Reliability
If physical mixtures of angiotensin II receptor antagonists and NEP inhibitors are used, then dual mechanism action is achieved, but therapeutic efficacy is limited
Solution Approach 1:
The patent creates a supramolecular complex with specific stoichiometric ratios (a:b) between EXP3174 and AHU377, establishing a defined and stable compositional relationship. This structured combination provides enhanced therapeutic efficacy compared to physical mixtures while maintaining composition stability through the defined supramolecular architecture.
Data Source
AI summary
Uses of a complex of an angiotensin II receptor antagonist metabolite and a NEP inhibitor in treating heart failure, specifically related are uses of complex in preparing a medicament for use in heart failure with reduced ejection fraction (HFrEF).